Equillium (FRA:0FY) Other Long-Term Liabilities : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Equillium Other Long-Term Liabilities?

Equillium's other long-term liabilities for the quarter that ended in Dec. 2023 was €0.00 Mil.

Equillium's quarterly other long-term liabilities declined from Jun. 2023 (€0.00 Mil) to Sep. 2023 (€-0.00 Mil) but then increased from Sep. 2023 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

Equillium's annual other long-term liabilities declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€-0.00 Mil) but then increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

Equillium Other Long-Term Liabilities Historical Data

The historical data trend for Equillium's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Other Long-Term Liabilities Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Equillium Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Equillium Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Equillium Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Equillium's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (FRA:0FY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (FRA:0FY) Headlines

No Headlines